Back to News listings

DNAe Appoints Alison Howie as Vice President of Commercial

London, UK and Carlsbad, CA, USA – 28 June 2021 – DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, has appointed Alison Howie as Vice President of Commercial with immediate effect.

Alison brings over 25 years of experience in the life sciences and diagnostics industries, during which she has held a number of senior marketing and business development roles. Joining DNAe’s senior management team, she will take the lead on commercial and market-orientated functions.

Alison worked for over eight years at Thermo Fisher Scientific, where she held leadership positions including Vice President of Marketing & Product Development and Vice President of R&D and Business Development for the company’s Microbiology business.

As well as her large multinational experience Alison has also spent time as an executive and leader in small and medium sized enterprises, including most recently two years as Chief Commercial Officer and Chief Product Officer at Ixico, a specialist provider of data analytics to Life Science clients. She has also worked as a managing consultant at PA Consulting, advising a range of clients on innovation, product launch and commercial scale-up.

Alison holds a BSc in Chemistry and an executive MBA from the London Business School.

Commenting on Alison’s appointment, Samuel Reed, CEO of DNAe, said: “We are happy to welcome Alison. She has a fantastic track record of leadership, business development and strategic insight in our industry, further strengthening our great team as we take the next exciting step in our journey to bring our LiDia-SEQ™ diagnostic platform to patients.”

Alison Howie commented: “I’m excited to be joining DNAe at a time of rapid company development and I look forward to helping to build on its success to date, leading the company’s commercial activities to deliver on its promise to bring state-of-the-art diagnostic innovation to the point of need.”

Alison Howie. High-resolution images available on request.

- ENDS -

Contact Details


Samuel Reed, CEO, DNAe Group

Please contact me via Instinctif (see below)

Instinctif Partners (media relations)

Tel: +44 (0) 7792 472 293

Tim Watson / Katie Duffell


About DNAe –

DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring. It is developing LiDia-SEQ™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians.

DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. This includes a range of tests, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to detect and identify infections that lead to sepsis. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease. A pipeline of follow-on tests is in development for viruses and cancer testing and monitoring.

The Biomedical Advanced Research and Development Authority (BARDA), a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), awarded DNAe a contract worth up to $51.9 million, if all options are awarded, to develop its diagnostic platform, initially for antimicrobial-resistant infections.

A private company, with facilities in London, UK and Carlsbad, CA, USA, DNAe’s major shareholder is Genting Berhad, a Malaysian-based global investor with a growing portfolio of investments in cutting-edge life sciences companies.

Back to News listings